渝东北地区441例白血病患者融合基因表达特点分析

Analysis of Expression Characteristics of Fusion Gene in 441 Patients with Leukemia in Northeastern Chongqing

目的探讨渝东北地区白血病患者融合基因表达特点。方法选取2017年1月~2019年9月期间于重庆三峡中心医院就诊的白血病患者441例,用实时荧光定量逆转录-聚合酶链反应(FQ-RT-PCR)法检测其43种白血病融合基因的表达情况。结果 441例患者中,检出193例患者有融合基因表达,其中BCR/ABL为75.13%(145/193),AMLETO为8.29%(16/193),PML-RARa为6.22%(12/193),MLL-AF9为4.15%(8/193),CBFβ-MYH11为2.59%(5/193),MLL-AF4,WT1和E2A-PBX1均为0.52%(1/193);MLL-AF6,MLL-AF10,ELL,ENL联合阳性率为1.55%(3/193),WT1和PML-RARa联合阳性率0.52%(1/193),其余基因未检出。结论融合基因的表达在白血病的诊断和疗效评估中起重要作用。

Objective To investigate the expression characteristics of fusion gene in leukemia patients in northeastern Chongqing. Methods 441 leukemia patients were selected from January 2017 to September 2019 in Chongqing Three Gorges Central Hospital, and the expression of 43 leukemia fusion genes was detected by FQ-RT-PCR method. Results Of the 441 patients, 193 patients were detected with fusion gene expression, of which BCR/ABL expression was the most common, accounting for 75.13 %(145/193), AML-ETO was 8.29 %(16/193)for second, PML-RARa was 6.22 %(12/193) for third, MLLAF9 was 4.15%(8/193) and CBF β-MYH11 was 2.59(5/193). MLL-AF4, WT1 and E2 A-PBX1 were all 0.52%(1/193). The positive rates of MLL-AF6, MLL-AF10, ELL and ENL were 1.55%(3/193). WT1 and PML-RARa were 0.52%(1/193),and the remaining genes were not detected. Conclusion The expression of fusion gene plays an important role in the diagnosis and evaluation of leukemia.